Research in contextEvidence before this studyDespite the use of powerful immunosuppression after kidney transplantation, allograft rejection, and most importantly antibody-mediated rejection, remains a strong predictor of graft failure. The diagnosis of antibody-mediated rejection is made on kidney allograft biopsies performed at the time of decline in glomerular filtration rate or appearance of proteinuria. Because antibody-mediated rejection can occur in the absence of immediate clinical signs or changes in these graft functional characteristics, some centers also perform kidney allograft biopsies at fixed time points (surveillance biopsies). Glomerular filtration rate and proteinuria are non-specific markers for antibody-mediated rejection, as many other immunological and non-immunological injuries can disturb graft function. More accurate non-invasive diagnostic markers are thus needed, with better sensitivity and specificity for antibody-mediated rejection than estimated glomerular filtration rate and proteinuria. We have systematically followed up and reviewed the scientific literature related to the development of non-invasive biomarkers for antibody-mediated rejection of kidney allografts. We focused on PubMed and Scopus for papers that report on non-invasive diagnostic markers for antibody-mediated kidney allograft rejection. We found only few independently validated non-invasive peripheral blood biomarkers for acute rejection. None of these markers were further developed or specific for diagnosis of antibody-mediated rejection.Added value of this studyIn this study, we identified and independently validated a novel non-invasive biomarker for antibody-mediated kidney allograft rejection in peripheral blood. To our knowledge, this is the first study to report on a biomarker with sufficiently good diagnostic accuracy for antibody-mediated rejection to be useful for clinical care of kidney transplant recipients. The diagnostic accuracy of the 8-gene assay for antibody-mediated rejection was superior to that of classical clinical indicators, and the assay offered additional benefit in clinical decision-making to perform or not to perform a biopsy for diagnosis of antibody-mediated rejection. We were able to show that the diagnostic accuracy of the 8-gene assay was retained in different clinical scenarios: early and late after transplantation, at time of stable graft function and at time of graft dysfunction.Implications of all the available evidenceOur results indicate that kidney transplant recipients suffering from antibody-mediated rejection can be identified by our newly developed non-invasive 8-gene assay. The 8-gene assay can serve as a clinical decision aid whether or not to perform an invasive biopsy for confirmation of antibody-mediated rejection at times of clinical suspicion. In routine follow-up of stable kidney transplant patients, this biomarker shows potential for more timely detection of often-missed subclinical antibody-mediated rejection and prompt initiation of targeted therapies after confirmative histological diagnosis, before chronic damage has developed and before the disease process becomes irreversible.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Antibody-mediated rejection is recognized as a primary cause of graft failure after kidney transplantation \[[@bb0005], [@bb0010], [@bb0015]\]. It is hallmarked histologically by inflammation and C4d deposition in peritubular capillaries, glomerulitis, intimal arteritis and expansion/duplication of the glomerular basement membrane \[[@bb0020]\].

Currently, the diagnosis of antibody-mediated rejection after kidney transplantation is made based on histological assessment of invasive kidney biopsies according to the regularly updated Banff international consensus \[[@bb0020]\]. Antibody-mediated rejection can be diagnosed in clinically indicated biopsies at time of graft functional problems (rise in serum creatinine or proteinuria), but can also occur subclinically, without changes in these graft functional parameters. Subclinical antibody-mediated rejection also associates with increased risk of graft failure \[[@bb0025]\] but often remains undetected, unless protocol-specified (surveillance) kidney biopsies are performed \[[@bb0010],[@bb0030]\]. Such protocol-specified biopsies are routinely performed in some centres, but not all, at varying time after transplantation.

Based on the association between antibody-mediated rejection and kidney graft failure, and the impossibility to repeatedly perform invasive protocol-specified biopsies, non-invasive diagnostic markers are needed with better sensitivity and specificity than eGFR and proteinuria \[[@bb0010],[@bb0025],[@bb0035]\]. Other groups have suggested non-invasive markers for antibody-mediated rejection, primarily assessed in urine samples \[[@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065]\]. Additional validation of these markers is necessary to support their potential clinical value \[[@bb0070], [@bb0075], [@bb0080]\].

Kidney allograft rejection is associated with molecular changes in renal allograft tissue, which reflect transcription changes in resident cells (e.g. interferon-gamma inducible changes in the donor endothelium) or changes in cell populations, like infiltration and activation of effector T cells and macrophages in T- cell mediated rejection or margination and activation of natural killer cells in antibody-mediated rejection \[[@bb0085],[@bb0090]\]. As these graft infiltrating cells are activated primarily in lymphoid organs before travelling and infiltrating the allograft \[[@bb0095]\], we hypothesized that the molecular changes that occur in renal allograft biopsies with antibody-mediated rejection could also be reflected by changes in circulating immune cells.

Given the lack of non-invasive, sufficiently validated markers for antibody-mediated rejection, we aimed to develop and validate an mRNA-based gene set in peripheral blood that is able to non-invasively rule out or detect ongoing antibody-mediated rejection after kidney transplantation.

2. Methods {#s0025}
==========

2.1. Study design, patient population and sample collection {#s0030}
-----------------------------------------------------------

This part of the BIOMArkers of Renal Graft INjuries (BIOMARGIN) study ([www.biomargin.eu](http://www.biomargin.eu){#ir0015}) is a multicentre, prospective, multiphase study, performed in four European transplant centres (Hôpital Necker Paris, France; University Hospitals Leuven, Belgium; Medizinische Hochschule Hannover, Germany; and Centre Hospitalier Universitaire Limoges, France). Samples were prospectively and consecutively collected at time of renal allograft biopsies, between June 2011 and August 2016. In the four clinical centres, protocol renal allograft biopsies were performed at 3, 12, and sometimes at 24 months after transplantation, according to local centre practice, in addition to clinically indicated biopsies (biopsies at time of graft dysfunction). All adult patients who had received a single kidney allograft at these institutions and who provided written informed consent, were eligible. Recipients of combined transplantations were excluded. All transplantations were performed with negative complement-dependent cytotoxicity cross-matches. Institutional review boards and national regulatory agencies (when required) approved the study protocol at each clinical centre.

The study was divided in three phases. In the discovery phase, blood and biopsy samples were used for genome-wide expression analysis. We selected samples based on availability and histological criteria of concomitant renal allograft biopsies (excluding cases with diagnosis of glomerulonephritis or polyomavirus nephropathy, and cases with unclear diagnosis). Based on local biopsy readings, a first selection was made, which was then further refined by judgment of the clinical courses and final confirmation by central pathology, independent from the original centre (see the Supplementary Appendix). The same study design was used for the second derivation phase, for targeted validation of the results obtained in the discovery set, and derivation of the multigene marker. In the validation cohort, all samples with concomitant adequate renal allograft biopsy histology, prospectively collected according to the BIOMARGIN protocol between June 24, 2014 and July 2, 2015 were serially included. In this cohort, no selection was made on histology, demographics, time or any other factor than sample availability. In this validation cohort, the analyses were entirely based on central pathology scores.

2.2. Primary and secondary end points {#s0035}
-------------------------------------

The primary end point was the diagnostic accuracy of a multigene marker for antibody-mediated rejection in the validation cohort in relation to the current gold standard of tissue pathology, based on the area under the receiver operating characteristic curve (ROC AUC). Secondary endpoints were the diagnostic accuracy in specific clinical situations (at time of graft dysfunction leading clinicians to perform an indication biopsy versus at time of stable graft function, early (\<1 year) versus later (\>1 year) after transplantation), and net benefit for clinical decision-making.

2.3. Sample collection and biopsy scoring {#s0040}
-----------------------------------------

Peripheral blood samples were collected at time of the renal allograft biopsies, directly in PAXgene Blood RNA tubes® (PreAnalytiX GmbH, a Qiagen/ BD Company, Switzerland). Two needle cores were taken at each kidney allograft biopsy. One was used for histology, at least half of the other one was immediately stored in Allprotect Tissue Reagent® (Qiagen Benelux BV, Venlo, The Netherlands) for RNA expression analysis (in the discovery set). All biopsies were rescored semiquantitatively according to the updated Banff 2017 classification \[[@bb0020]\]. Index test results were not available to assessors of the histopathological scoring (reference standard), whereas reference standard results and clinical information were available to the readers of the index test.

In the discovery cohort, RNA extracted from blood and biopsies was hybridized onto Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix Inc., High Wycombe HP10 0HH, UK). In the derivation and validation cohorts, RNA expression analysis of mRNA extracted from blood samples was evaluated by real-time polymerase chain reaction (RT-PCR) using OpenArray® technology on the Quantstudio™ 12 K Flex Real-Time PCR System (Life Technologies Europe BV, Ghent, Belgium) with ACTB, GAPDH and SDHA as endogenous controls. Details on blood and biopsy sample collection and gene expression analysis are provided in the Supplementary Appendix.

2.4. Statistical analysis {#s0045}
-------------------------

In the discovery phase, robust-multiarray average-normalized mRNA expression data of the 117 peripheral blood samples and 95 biopsies were analyzed in a statistical pipeline developed under the R framework in an extension of the *biosigner* R package as developed for this study \[[@bb0100]\], with addition of Elastic-Net and Shrunken Centroids multivariate methods to the Sparse Partial Least Squares (SPLS), Random Forrest and Support Vector Machines-Recursive Feature Elimination (SVM-RFE) multivariate methods already available in the biosigner package. More information on the constructed statistical pipeline and determination of a multivariate score for antibody-mediated rejection (ABMR score) and T-cell mediated rejection (TCMR score) is given in the Supplementary Appendix. A multivariate score \> 0·25 was considered as specific for antibody-mediated and/or T-cell mediated rejection. Ingenuity Pathway Analysis (IPA, Build: 478438 M Content version: 44691306) was used for canonical pathway enrichment analysis.

In the derivation phase, we identified the multivariate combination of transcripts that lead to the best model performance, based on the extended list of transcripts obtained in the discovery phase. This identification of the multigene signature was done by ranking a combination of genes according to the C-statistic of logistic regression models trained on this combination and estimated under a 3-folds cross validation. Instead of identifying the best combination as the final multigene signature, we integrated the combinations obtained by the top K models (see Supplementary Appendix). The best multigene signature was then used to build a multivariable logistic regression model in a nested-cross validation approach on the derivation cohort. The ensuing logistic regression model (intercept and estimations) was then locked and represented the final multigene assay**.**

The diagnostic accuracy of the locked multigene signature and logistic regression model calculated in the derivation phase was then evaluated on the validation cohort. We used receiver operating characteristic (ROC) curves to evaluate the C-statistic (area under the curve, AUC) of the multigene assay. The optimal marker threshold from the derivation phase, at the highest combination of sensitivity and specificity (which are independent of disease prevalence), was then evaluated in this validation cohort. In addition, arbitrarily defined low and high thresholds with respectively high negative and positive predictive values (which are dependent on actual disease prevalence) were evaluated in the validation cohort.

Finally, post-hoc sensitivity analyses were performed to evaluate the accuracy of the marker in specific clinical situations. The net benefit of the 8-gene marker for clinical decision-making was evaluated using decision curve analysis \[[@bb0105]\]. To allow for comparison and assess added value of the 8-gene assay compared with clinical parameters alone, we built a clinical model using the 8 clinical parameters that were differently prevalent in the ABMR vs. no AMBR group. This model was built and cross-validated in the discovery and derivation phases combined and then assessed in the independent validation phase. The diagnostic performances of the clinical model, the 8-gene assay and an integrated model (adding the 8-gene assay to the clinical model) were assessed and compared using ROC CONTRAST and random forest out-of-bag error rates (using 500 trees). For variance analysis of continuous clinical variables in different groups, non-parametric Wilcoxon-Mann-Whitney U, non-parametric ANOVA and parametric one-way ANOVA were used. Dichotomous variables were compared using the chi-square test. R \[[@bb0110]\], SAS (version 9.4; SAS institute, Cary, NC) and GraphPad Prism (version 7; GraphPad Software, San Diego, CA) were used for data presentation. Normalized signal intensities and. CEL files of the transcriptomic data were deposited at the NIH Gene Expression Omnibus <http://www.ncbi.nlm.nih.gov/geo> under the series accession number GSE 129166) and the microarray data were handled in accordance with the MIAME (Minimum Information About a Microarray Experiment) guidelines. The BIOMARGIN study is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0025}, number [NCT02832661](NCT02832661){#ir0030}. The checklist according the STARD guidelines for diagnostic accuracy studies was completed and is included in the Supplementary Appendix (Table S9).

2.5. Study approval {#s0050}
-------------------

All patients provided informed written consent.

3. Results {#s0055}
==========

3.1. Baseline characteristics {#s0060}
-----------------------------

We included 687 peripheral blood samples from 630 patients obtained at the time of a renal allograft biopsy, 120 with antibody-mediated rejection and 567 without ([Fig. 1](#f0005){ref-type="fig"}). In the discovery phase, 117 blood samples and 95 biopsy samples were used for genome-wide expression analysis from 117 patients, in a case-control study design. In the derivation phase, we included 183 samples from 183 individual patients, again in a case-control setting. In the independent validation cohort, 387 consecutively collected and unselected samples from 365 patients were included in the analyses; 56 samples were excluded, 49 because of inadequate biopsy histology and seven because of incompleteness of the gene expression profile. Patients\' demographics and clinical characteristics of the three independent peripheral blood sample sets are provided in [Table 1](#t0005){ref-type="table"} and Table S1 in the Supplementary Appendix. There were significant differences between patients with versus without antibody-mediated rejection in some baseline characteristics, reflecting the background risk for development of antibody-mediated rejection as shown in [Table 2](#t0010){ref-type="table"}. Details on the clinical characteristics of the biopsy samples used for micro-array gene expression (*N* = 95) were provided separately \[[@bb0090]\]. Histological characteristics of the biopsies in the validation set are provided in Table S2.Fig. 1Study design. Peripheral blood samples were obtained at the time of a renal allograft biopsy in four European transplant centres. In the discovery and derivation cohort, samples were selected based on availability and histological criteria of concomitant renal allograft biopsies (excluding cases with diagnosis of glomerulonephritis or polyomavirus nephropathy, and cases with unclear diagnosis), while graft function was not taken into account. In the validation cohort, all samples with concomitant adequate renal allograft biopsy histology, prospectively collected between June 24, 2014 and July 2, 2015, were serially included without selection on histology, demographics or time. The gene expression profile was not complete in seven of these samples, leading to a total of 387 cases in the validation phase. ABMR = antibody-mediated rejection.Fig. 1Table 1Characteristics of the patients and biopsies included in the validation cohort (*N* = 365 patients, 387 biopsies).Table 1VariableMean (median) ± standard deviation (min -- max) or no. (%)Transplant characteristics (N = 365 patients)Recipient age at transplantation (years)50·2 (52·2) ± 15·3 (2·7--78·5)Recipient age at time of biopsy (years)52·4 (54·1) ± 14·4 (19·0--79·6)Recipient sex (male/female)224/141 (61·4%/38·6%)Repeat transplantation64 (17·5%)Recipient ethnicity (European/ Asian/ African/ Other)318/3/6/35[⁎](#tf0005){ref-type="table-fn"} (87·8%/0·8%/1·7%/9·7%)Donor age (years)50·6 (52·0) ± 15·5 [⁎](#tf0005){ref-type="table-fn"} (5·0--91·0)Donor sex (male/female)177/180[⁎](#tf0005){ref-type="table-fn"} (50·4%/49·6%)Deceased/Living donor278/83[⁎](#tf0005){ref-type="table-fn"} (77·0%/23·0%)Heart-beating/ Non-heart-beating donor250/28[⁎](#tf0005){ref-type="table-fn"} (89·9%/10·1%)Cold ischemia time (hours)12·1[⁎](#tf0005){ref-type="table-fn"} (12·6) ± 7·8 (0·27--35·8)  Biopsy characteristics (*N* = 387 biopsies)Indication/protocol biopsy134/253 (34·6%/65·4%)Time after transplantation (days)908 (359) ± 1733 (6--12,564)Biopsy time after transplantation\< 1 year207 (53·5%)\> 1 year180 (46·5%)MDRD eGFR, (ml/min/1·73 m^2^)43·0 (41·8) ± 17·5 (5·8--96·2)Proteinuria (g/g creatinine)0·4[⁎](#tf0005){ref-type="table-fn"} (0·1) ± 1·0 (0·0--8·0)  Immunosuppression at time of biopsyCyclosporine40 (10·3%)Tacrolimus331 (85·5%)Mycophenolate320 (82·7%)Azathioprine9 (2·3%)mTOR inhibitor49 (12·7%)Corticosteroids352 (91·0%)Histological diagnosisNo rejection330 (85·3%)T-cell mediated rejectionBorderline changes15 (3·9%)Grade 1 or 24 (1·0%)Antibody-mediated rejection41 (10·6%)Mixed rejection\^3 (0·8%)Interstitial fibrosis/tubular atrophyGrade 0182 (47·0%)Grade 193 (24·0%)Grade 264 (16·5%)Grade 348 (12·4%)Polyomavirus-associated nephropathy14 (3·6%)De novo/recurrent glomerulonephritis26 (6·7%)[^2][^3]Table 2Comparison between cases with antibody-mediated rejection vs. without antibody-mediated rejection in the validation cohort (*N* = 387). For variance analysis of continuous variables *t*-test was used; dichotomous variables were compared with the Chi-square test.Table 2VariableAntibody-mediated rejection (N = 41)No antibody-mediated rejection (N = 346)*P* value*Mean ±* *SD*\
*or No. (%)Mean ±* *SD*\
*or No. (%)*Recipient age at transplantation (years)42·9 ± 17·350·8 ± 14·80·002Recipient age at time of biopsy (years)50·5 ± 14·452·7 ± 14·40·37Recipient sex (male/female)16/25 (39·0%/61·0%)224/122 (64·7%/35·3%)0·001Recipient ethnicity[⁎](#tf0010){ref-type="table-fn"}\
(European/Asian/African/Other)38/0/0/3 (92·7%/0%/0%/7·3%)300/3/6/34 (86·7%/0·9%/1·7%/9·8%)0·77Donor age (years) [⁎](#tf0010){ref-type="table-fn"}41·2 ± 17·551·3 ± 14·9\<0·0001Donor sex[⁎](#tf0010){ref-type="table-fn"} (male/female)24/14 (63·2%/36·8%)168/173 (49·3%/50·7%)0·10Deceased/Living donor [⁎](#tf0010){ref-type="table-fn"}34/5 (87·2%/12·8%)261/83 (75·9%/24·1%)0·11Heart-beating/ Non-heart-beating donor[⁎](#tf0010){ref-type="table-fn"}32/2 (94·1%/5·9%)231/30 (88·5%/11·5%)0·32Cold ischemia time (hours)[⁎](#tf0010){ref-type="table-fn"}13·3 ± 6·912·0 ± 7·90·36Repeat transplantation (yes/no)60/286 (17·3%/82·7%)9/32 (22·0%/78·0%)0·92Indication/protocol biopsy30/11 (73·2%/26·8%)104/242 (30·1%/69·9%)\<0·0001Time after transplantation (days)2806·0 ± 3233·7683·5 ± 1293·50·0002MDRD eGFR, (ml/min/1.73 m^2^)34·7 ± 21·443·9 ± 16·70·01Proteinuria (g/g creatinine)[⁎](#tf0010){ref-type="table-fn"}1·4 ± 1·90·3 ± 0·70·0006Presence of DSA18 (43·9%)46 (13·3%)\<0·0001[^4]

3.2. Discovery of transcripts specific for antibody-mediated rejection {#s0065}
----------------------------------------------------------------------

In peripheral blood and biopsy samples, respectively 970 and 783 probesets (730 and 576 individual genes) had an ABMR score \> 0·25. Pathway enrichment analysis of the biopsy signature was previously published \[[@bb0090]\]. Based on ABMR scores in peripheral blood and biopsies, 2 genelists were determined (Fig. S1 in the Supplementary Appendix). In both genelists, there was significant enrichment in natural killer cell signaling, crosstalk between dendritic and natural killer cells, communication between innate and adaptive immune cells and antigen presentation pathways. Predicted upstream factor analysis identified interferons and interferon regulatory factors as the most likely upstream regulators (Table S3 in the Supplementary Appendix).

3.3. Gene signature identification and model development in the derivation cohort {#s0070}
---------------------------------------------------------------------------------

From the genelists obtained in the discovery phase, we selected 44 transcripts for RT-PCR analysis in the derivation cohort, based on combinations of ABMR and TCMR scores in blood and allograft biopsies, robustness of the results with different probesets of the same gene and by their involvement in relevant canonical pathways (Table S4 in the Supplementary Appendix). First, 26 genes with ABMR score \> 0·25 and TCMR score \< 0·20 in blood were selected (of these selected transcripts, nine also had a high ABMR score \> 0·25 in kidney biopsies). We additionally selected 17 genes with an ABMR score \> 0.25 in biopsies and ABMR score \> 0.20 in peripheral blood. Finally, given the biological homology of *CXCL11* with *CXCL10* and an ABMR score of *CXCL11* of 0·49 in biopsy samples (but only 0·08 in blood), we added *CXCL11* to the gene panel in the derivation phase. The univariate associations of the expression of these 44 genes with rejection phenotypes are shown in Fig. S2 in the Supplementary Appendix. From these 44 genes, a gene signature specific for antibody-mediated rejection was identified on the samples of the derivation cohort (*N* = 183), and included the following eight genes: *CXCL10, FCGR1A, FCGR1B, GBP1, GBP4, IL15, KLRC1, TIMP1*. More information on the role of these eight genes in ABMR is provided in Table S5. Subsequently, this 8-gene signature was used to build a logistic regression model with nested loop internal cross-validation for discrimination between cases with and without antibody-mediated rejection in the derivation cohort. Applied to the samples of the derivation cohort, this gene signature and logistic regression model yielded a ROC AUC of 78·1% (95% confidence interval \[CI\], 70·7 to 85·6; *p* \< 0·0001)([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Diagnostic accuracy of the 8-gene assay for non-invasive diagnosis of antibody-mediated rejection in the validation cohort (*N* = 387). The left panel shows the 8-gene assay score in cases with versus without antibody-mediated rejection. The middle panel shows the distribution of cases with antibody-mediated rejection across all scores of the 8-gene assay. The right panel shows the ROC curves for samples with versus without antibody-mediated rejection, with presentation of the area under the receiver operating characteristic curve (ROC AUC) and the 95% confidence interval.Fig. 2

3.4. Diagnostic accuracy of the 8-gene assay in the validation cohort {#s0075}
---------------------------------------------------------------------

The 8-gene signature and logistic regression model built and locked on the derivation cohort were evaluated on the 387 samples collected in the validation cohort, which contained 41 cases with antibody-mediated rejection (10·6%), representing the natural prevalence of this phenotype in the cohort of biopsies performed at the participating centres. The 8-gene assay reached a ROC AUC of 79·9% (95% CI, 72·6 to 87·2; *p* \< 0·0001)(Fig. S3 in the Supplementary Appendix). When we evaluated the diagnostic accuracy for discrimination between pure antibody-mediated rejection (*N* = 38) and pure borderline changes and T-cell mediated rejection (*N* = 13 and 3 respectively), the 8-gene assay reached a ROC AUC of 82·2% (95% CI 70·7 to 93·8, *p* = 0·001), and 79·3% (95% CI, 71·6 to 86·9; p \< 0·0001) for discrimination between pure antibody-mediated rejection (N = 38) and absence of rejection (*N* = 330). This 8-gene assay was not diagnostic for the group of T-cell mediated rejections (containing mostly borderline changes) (Fig. S4 in the Supplementary Appendix).

We next validated the cut-off value of the 8-gene assay that was determined in the derivation phase (Fig. S5 in the Supplementary Appendix). The optimal cut-off from the derivation phase for the 8-gene biomarker (−1·08) had a sensitivity of 73·2%, specificity of 75·7%, Youden index of 0·49, positive predictive value of 26·3% and negative predictive value of 96·0% in the validation cohort ([Table 3](#t0015){ref-type="table"} and Fig. S6 in the Supplementary Appendix).Table 3Diagnostic accuracy of the 8-gene marker for non-invasive diagnosis of antibody-mediated rejection in the independent validation cohort (*N* = 387).Table 3Diagnostic Accuracy (ROC AUC)Accuracy\
(Total correct/total)SensitivitySpecificityPositive Predictive ValueNegative Predictive ValuePopulation (N = ABMR/total)% (95% CI)%%%%%Validation cohortAll biopsies (N = 41/387)79·9% (72·7--87·2) Low threshold^§^ (−2·50)*p* \< 0·000135·1%95·1%28·0%13·5%98·0% Optimal threshold\* (−1·08)75·5%73·2%75·7%26·3%96·0% High threshold^§^ (0·50)89·1%22·0%97·1%47·4%91·3%  Post-hoc sensitivity analysesEarly biopsies \<1 year (*N* = 10/207)90·9% (85·3--96·4) Low threshold (−2·50)p \< 0·000133·8%100%30·5%6·8%100% Optimal threshold (−1·08)79·2%90·0%78·7%17·6%99·4% High threshold (0·50)93·2%20·0%97·0%25·0%96·0%Late biopsies \>1 year (*N* = 31/180)73·5% (63·6--83·4) Low threshold (−2·50)p \< 0·000136·7%93·5%24·8%20·6%94·9% Optimal threshold (−1·08)71·1%67·7%71·8%33·3%91·5% High threshold (0·50)84·4%22·6%97·3%63·6%85·8%Biopsies at time of graft dysfunction\
(*N* = 30/134)75·3% (64·9--85·8) Low threshold (−2·50)p \< 0·000136·6%93·3%20·2%25·2%91·3% Optimal threshold (−1·08)71·6%73·3%71·1%42·3%90·2% High threshold (0·50)79·1%26·7%94·2%57·1%81·7%Biopsies at time of stable graft function (N = 11/253)83·4% (75·4--91·3) Low threshold (−2·50)p \< 0·000134·4%100%31·4%6·2%100% Optimal threshold (−1·08)77·5%72·7%77·7%12·9%98·4% High threshold (0·50)94·5%9·1%98·3%20·0%96·0%[^5]

3.5. Sensitivity analysis {#s0080}
-------------------------

The 8-gene assay retained its accuracy for antibody-mediated rejection in patients with stable graft function and at time of graft dysfunction, within the first year and also later after transplantation ([Table 3](#t0015){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}, Table S6 in the Supplementary Appendix). In all scenarios, the 8-gene assay allowed to rule out ongoing antibody-mediated rejection with high negative predictive values. However, the power was low in these sub-analyses, and these accuracy parameters should be interpreted cautiously. The 8-gene assay reached universal high specificities for antibody-mediated rejection, but the positive predictive value was lower due to the low prevalence of this disease in the validation cohort, especially in protocol-specified biopsies. From this, the positive predictive value was higher at time of graft dysfunction than in stable graft function. If restricted to cases with donor-specific antibodies (*N* = 64), the positive predictive value of the 8-gene assay was even higher: at the optimal threshold (−1·08), positive predictive value was 57·1%, with sensitivity of 66·7%, specificity of 80·4%, Youden index of 0·47 and negative predictive value of 86·0%.Fig. 3Diagnostic accuracy of the 8-gene assay for antibody-mediated rejection in specific subgroups in the validation set (*N* = 387). Post-hoc sensitivity analysis of the 8-gene marker according to time after transplantation is shown in panel A and according to stable graft function vs. graft dysfunction in panel B.Fig. 3

3.6. Correlation of the 8-gene assay with histological and clinical variables {#s0085}
-----------------------------------------------------------------------------

The 8-gene assay correlated with graft functional parameters like eGFR and proteinuria, and with histological lesions diagnostic for antibody-mediated rejection like glomerulitis, peritubular capillaritis, microvascular inflammation, and transplant glomerulopathy in the validation cohort (Table S7 in the Supplementary Appendix). Distribution of the 8-gene assay score per histological lesion grade is shown in [Fig. 4](#f0020){ref-type="fig"}. There was no correlation with histological lesions of T-cell mediated rejection. The 8-gene biomarker did not associate with diagnosis of glomerulonephritis, polyomavirus associated nephropathy or interstitial fibrosis with tubular atrophy. A weak association with recipient gender (*p* = 0·04) was found. No other donor-recipient demographics associated with the 8-gene assay.Fig. 4Distribution of the 8-gene assay score per histological lesion grade in the validation cohort (N = 387). The 8-gene assay score was significantly associated with lesions of antibody-mediated rejection. Significance was assessed with nonparametric one-way ANOVA and pairwise comparisons with *t*-test. Significance was apparent for higher severity grades of lesions associated with antibody-mediated rejection (glomerulitis, peritubular capillaritis, microvascular inflammation score, transplant glomerulopathy). No significant association was present with lesions of T-cell mediated rejection (tubulitis, interstitial inflammation) or non-specific chronic damage (interstitial fibrosis, tubular atrophy). g = glomerulitis; ptc = peritubular capillaritis; mvi = microvascular inflammation; cg = transplant glomerulopathy; i interstitial inflammation; t = tubulitis; v = intimal arteritis; C4d = C4d deposition in peritubular capillaries; ci = interstitial fibrosis; ct = tubular atrophy; cv = intimal fibrosis; ah = arteriolar hyalinosis. ns = not significant, \**p* \< 0·05,\*\*p \< 0·01,\*\*\*p \< 0·001,\*\*\*\*p \< 0·0001.Fig. 4

3.7. Comparison with traditional biomarkers and added clinical value of the 8-gene assay {#s0090}
----------------------------------------------------------------------------------------

The 8-gene assay associated with diagnosis of antibody-mediated rejection, independent of traditional factors associating with antibody-mediated rejection (female gender, recipient age, time after transplantation, presence of donor-specific antibodies and proteinuria) (Table S8 in the Supplementary Appendix). We next built and internally cross-validated a clinical model on the data from the discovery and derivation phase combined, which consisted of the 8 clinical parameters that differed between ABMR vs. no ABMR cases (donor-specific antibodies, proteinuria, eGFR, time after transplantation, recipient age at time of transplantation, donor age, recipient sex and protocol vs. indication biopsy). In the validation set, this clinical model reached an AUC of 77·3% (95% CI 68·5 to 86·0, *p* \< 0·0001). Adding the result of the 8-gene assay to the clinical model increased the diagnostic accuracy for ABMR to 88·0% (95% CI, 82·7 to 93·3; p \< 0·0001) (Fig. S7 in the Supplementary Appendix). Random forest out-of-bag error rates in the validation set were comparable for the 8-gene assay and the clinical model (14·99% and 14·73%, respectively). When adding the 8-gene assay to the clinical model the error rate dropped to 11·37%. In protocol biopsies (at time of stable graft function), the clinical model was not contributive (AUC of 55·7%, 95% CI, 37·2--74·2). Both in indication and protocol biopsies the 8-gene assay had added diagnostic value on top of the clinical model (Fig. S7 in the Supplementary Appendix). Decision curve analysis confirmed the net benefit of using the 8-gene assay for diagnosis of antibody-mediated rejection across the range of probability thresholds between 5% and 35% (Fig. S8 in the Supplementary Appendix).

4. Discussion {#s0095}
=============

In this multicentre, prospective, multiphase study we identified and validated an 8-gene expression assay in peripheral blood samples with good diagnostic accuracy for non-invasive diagnosis of antibody-mediated rejection. The 8-gene assay retained this accuracy both at time of stable graft function and at time of graft dysfunction, within the first year and also later after transplantation. The diagnostic accuracy of the 8-gene assay for antibody-mediated rejection was superior to that of clinical indicators, and the assay offered benefit in clinical decisions to perform or not perform a biopsy for diagnosis of antibody-mediated rejection.

This study is a landmark in the field of biomarker discovery and development in renal transplantation in several aspects. First, its multiphase study design with independent discovery, derivation and validation sets allowed for robust biomarker development and validation \[[@bb0075],[@bb0080]\]. After nested loop internal cross-validation in the derivation set, we performed independent external validation of the locked and fully specified model in a representative population with natural prevalence of antibody-mediated rejection, using the same technology platform. Second, stringent phenotypic selection with central re-assessment was applied, minimizing the interobserver variability in the current gold standard for diagnosis of rejection and reference standard for performance of the biomarker. Third, the comparison with an internally cross-validated and externally validated clinical model, and assessment of the net benefit of using this 8-gene assay indicate the clinical usefulness of this marker on top of routinely available clinical markers.

The unbiased transcriptomic analysis on the discovery set illustrated that the molecular changes that occur in renal allograft biopsies with antibody-mediated rejection, primarily related to immune regulation, are also reflected in transcriptional differences in peripheral blood. The selected gene transcripts in our study come from biologically plausible molecular pathways, based on gene pathway enrichment analyses. Especially natural killer cells and their interplay with dendritic cells are known to be notorious players in humoral rejection \[[@bb0115]\]. The significant enrichment of these pathways in our gene transcripts corroborates the specificity of our marker for antibody-mediated rejection. Furthermore, the eight individual genes have relevant pathophysiological functions and most have references to rejection as found from proposed gene transcript lists \[[@bb0020],[@bb0085]\].

In addition, we assessed the accuracy of this biomarker in different clinical scenarios. The clinical value of a biomarker in renal transplantation depends on the setting in which biopsies are performed, as we also observed in our post-hoc sensitivity analyses. The better diagnostic accuracy of our marker in the first year after transplantation is relevant, as therapeutic implications will be greatest when antibody-mediated rejection is detected early, before chronic damage has developed and the disease becomes irreversible \[[@bb0015],[@bb0120]\]. The high negative predictive value and high sensitivity of our 8-gene assay in all settings indicates that the assay can be used to rule out antibody-mediated rejection, both at time of graft dysfunction and at time of stable graft function.

Another strength of our study is the comparison with readily available clinical information, where we illustrated the added value of the 8-gene assay both at time of stable graft function and at time of graft dysfunction. As protocol biopsies are not guided by clinical information, the clinical model is of little use in this scenario, and was outperformed by the 8-gene assay. Part of the relevance of this biomarker indeed lies in its accuracy independent of graft functional parameters (estimated glomerular filtration rate and proteinuria) as subclinical histological changes of antibody-mediated rejection often remain undetected but are nevertheless associated with an increased risk of graft failure \[[@bb0025],[@bb0030]\]. In centres that are currently not performing protocol-specified biopsies to detect subclinical rejection, it could be considered to include this biomarker in the follow-up of patients at increased risk of antibody-mediated rejection (e.g. patients with donor-specific antibodies) and restrict performing protocol-specified biopsies only to patients with a higher value of the 8-gene assay, when antibody-mediated rejection is not excluded. In centres that routinely perform protocol-specified biopsies, a low value of the 8-gene assay could be used to avoid performing the biopsy in such case. This indicates the usefulness of the biomarker and possibility to adapt cutoff values of the biomarker according to centre preference, as was illustrated using arbitrarily chosen low and high cutoffs. For further clinical implementation, validation of these cutoffs in the same way the optimal cutoff was validated, is still warranted.

Finally, the high specificity for antibody-mediated rejection at all instances is clinically meaningful, although the positive predictive value is lower, primarily related to the low prevalence of antibody-mediated rejection in this cohort. Yet, the decision curve analysis of our 8-gene assay confirmed that the test offers benefit in clinical decision making over the range of clinically reasonable thresholds for performing a biopsy. It can be anticipated that the positive predictive value of our test would be even higher in higher-risk cohorts, as was illustrated in our subanalysis of cases with donor-specific antibodies. In further clinical validation of this biomarker, the diagnostic performance in specific risk groups, at different time points and in different clinical situations will need to be addressed in larger populations.

Our study has several limitations. Definition of antibody-mediated rejection is a topic of active discussion, which makes our reference standard of histology imperfect \[[@bb0020]\]. This may have affected the final diagnostic accuracy of our 8-gene assay and re-evaluation of the diagnostic performance of our assay in updated versions of the Banff diagnostic classification will be needed. Moreover, given the inherent difficulties with histological diagnosis of antibody-mediated rejection as gold standard for diagnosis of antibody-mediated rejection (reproducibility, sampling error), better diagnostic accuracy of any test is not expected. In addition, the study design of the validation cohort did not allow evaluating the prognostic performance of the assay for future antibody-mediated rejection, or for prediction of outcome of patients with antibody-mediated rejection. Also, in clinical practice, the combination of our 8-gene assay with non-invasive mRNA markers for T-cell mediated rejection and chronic tubulo-interstitial injury, as were previously proposed \[[@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145]\], would be interesting to assess different graft injury processes simultaneously. Correlations of the marker with lesions like transplant glomerulopathy are rather weak, leaving biopsies in some cases indispensable for determining the degree of injury and the utility of treatment. As the vast majority of our population was treated with a calcineurin inhibitor-based immunosuppressive regimen, further studies are necessary to assess whether the 8-gene assay is also valuable in patients on other immunosuppressive regimens. The same remark applies for the fact that the majority of our population was of Caucasian ethnicity, requiring further studies to assess whether the 8-gene assay is also valuable in patients of other ethnical groups. Also, our validation cohort with real-life disease prevalence had very low incidence of TCMR, with a majority of the TCMR samples meeting only criteria for borderline changes. Although this reflects the natural disease prevalence in our clinical centres, this could differ from other clinical centres with different clinical practice, and perhaps overestimate the discriminative performance of our marker for ABMR versus TCMR.

In conclusion, we present a novel 8-gene biomarker with robust accuracy for non-invasive diagnosis of antibody-mediated rejection after kidney transplantation. Further evaluation and validation is warranted in larger prospective studies.
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[^1]: These authors contributed equally

[^2]: \^Mixed rejection cases are defined by co-occurrence of antibody-mediated rejection and T-cell mediated rejection.

[^3]: Missing data on donor age, donor gender, donor type, cold ischemia time, proteinuria, recipient ethnicity and induction therapy.

[^4]: missing data on recipient ethnicity, donor age, donor sex, deceased/living donor, heart-beating/non-heart-beating donor, cold ischemia time and proteinuria.

[^5]: \*The optimal threshold for the ROC curve was chosen in the derivation phase at maximum sensitivity and specificity. ^§^Low and high thresholds were arbitrarily selected in the independent validation cohort. ROC AUC = area under the receiver operating characteristic curve.
